/A first-in-human phase 1, multicenter, open-label study of CB-011, a next-generation CRISPR-genome edited allogeneic anti-BCMA immune-cloaked CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CAMMOUFLAGE trial).
Citation Map
The articles shown here are a subset.See the full list of articles below.
Citing (0)
Citation Count
Data not found
Cited By (0)
Citation Count